Corporate News
Certara Inc. (NASDAQ: CERT) experienced a 4.04 % increase during the 24‑hour period ending 11:36 PM Central Europe on Friday, 23 Nov 2026. The share price is currently approximately USD 10.33 on major exchanges.
- Shares Outstanding: 153.3 million
- Market Capitalisation: USD 1.6 billion
- Volume (last 24 hrs): USD 17.5 million
- Year‑to‑Date Performance: 15.29 % up since the end of last month
- 200‑Day Simple Moving Average: USD 7.22
- 52‑Week High: USD 12.94 (27 Oct 2025)
- 52‑Week Low: USD 4.45 (15 May 2026)
Related Stock Movements (Last 24 hrs)
| Company | Ticker | % Change | Current Price | Market Capitalisation |
|---|---|---|---|---|
| Cirrus Aircraft | 2507.HK | –1.67 % | HKD 39.1 | HKD 14.5 billion |
| Concentrix | CNXC | +2.92 % | USD 33.00 | USD 1.8 billion |
| Trump Media & Technology Group | DJT | +2.94 % | USD 6.40 | USD 1.9 billion |
| Establishment Labs | ESTA | +1.98 % | USD 63.80 | USD 1.9 billion |
| Astrana Health | ASTH | +1.77 % | USD 37.45 | USD 1.9 billion |
Concentrix
A filing by Synnex Technology International Corp. (Schedule 13G/A, SEC, 21 Oct 2026) reports that Synnex now holds roughly five % of Concentrix’s common shares, granting sole voting and disposal rights over that stake. The filing confirms the ownership level has crossed the ten‑percent threshold, triggering the amendment. No additional details regarding the transaction or its impact on governance were provided.
Trump Media & Technology Group
TMTG filed a Rule 425 form with the SEC on 22 Oct 2026, disclosing a proposed merger with energy company TAE Technologies. The filing includes financial profiles, expected benefits, timing, and potential risks. CEO Kevin McGurn highlighted strategic rationales, such as the company’s strengthened balance sheet, potential access to fusion‑derived energy, and new revenue streams from a covered‑call strategy. Plans to expand Truth Social, Truth+, and launch a high‑frequency “Truth API” were also outlined. Shareholder approvals and additional SEC filings will follow.
Astrana Health
Astrana Health’s price‑to‑earnings ratio is 45.58.
About Certara
Certara Inc. is a biotechnology firm specializing in the transformation of drug discovery and development through advanced biosimulation software and technology. The company aims to accelerate the delivery of medicines to patients, thereby improving health outcomes. Certara operates globally and is listed on the Nasdaq. For further information, visit www.certara.com .
